An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
An Extension Study of Venetoclax in Subjects With Advanced Non-Hodgkin's Lymphoma
Sponsor: AbbVie
This PHASE1 trial investigates Non-Hodgkin's Lymphoma and is currently completed. AbbVie leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2018 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .